Dupont Capital Management Corp Acquires 27,864 Shares of Zoetis Inc. (NYSE:ZTS)

Dupont Capital Management Corp raised its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 71.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 67,054 shares of the company's stock after acquiring an additional 27,864 shares during the period. Zoetis comprises approximately 1.2% of Dupont Capital Management Corp's portfolio, making the stock its 29th biggest holding. Dupont Capital Management Corp's holdings in Zoetis were worth $11,040,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Covea Finance grew its position in Zoetis by 20.3% during the first quarter. Covea Finance now owns 297,862 shares of the company's stock valued at $49,043,000 after acquiring an additional 50,293 shares during the last quarter. Private Wealth Partners LLC grew its position in Zoetis by 0.3% during the first quarter. Private Wealth Partners LLC now owns 76,512 shares of the company's stock valued at $12,598,000 after acquiring an additional 238 shares during the last quarter. River Street Advisors LLC grew its position in Zoetis by 7.5% during the first quarter. River Street Advisors LLC now owns 2,711 shares of the company's stock valued at $446,000 after acquiring an additional 188 shares during the last quarter. Roberts Wealth Advisors LLC grew its position in Zoetis by 0.9% during the first quarter. Roberts Wealth Advisors LLC now owns 19,162 shares of the company's stock valued at $3,155,000 after acquiring an additional 170 shares during the last quarter. Finally, Blue Trust Inc. grew its position in Zoetis by 23.4% during the first quarter. Blue Trust Inc. now owns 5,238 shares of the company's stock valued at $862,000 after acquiring an additional 992 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Performance

Shares of ZTS stock opened at $157.26 on Friday. The stock has a fifty day moving average of $159.58 and a 200 day moving average of $163.40. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33. The firm has a market capitalization of $70.01 billion, a price-to-earnings ratio of 28.23, a PEG ratio of 2.57 and a beta of 0.94. The company has a quick ratio of 1.04, a current ratio of 1.74 and a debt-to-equity ratio of 1.12.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 55.48% and a net margin of 27.12%. The company had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. During the same quarter last year, the firm posted $1.38 earnings per share. The firm's revenue was up 1.4% on a year-over-year basis. As a group, research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.27%. The ex-dividend date is Friday, July 18th. Zoetis's payout ratio is 35.91%.

Analyst Ratings Changes

Several research analysts have recently issued reports on ZTS shares. Stifel Nicolaus cut shares of Zoetis from a "buy" rating to a "hold" rating and cut their target price for the stock from $165.00 to $160.00 in a report on Wednesday. UBS Group cut their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Wall Street Zen upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Finally, Piper Sandler raised their target price on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Monday, May 12th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $212.13.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the firm's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the transaction, the executive vice president now owns 15,129 shares of the company's stock, valued at approximately $2,571,930. This trade represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.18% of the stock is currently owned by insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.